Xencor Revenue and Competitors

Monrovia, CA USA

Location

$133.4M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Xencor's estimated annual revenue is currently $77.3M per year.(i)
  • Xencor received $Undisclosed in venture funding in March 2018.
  • Xencor's estimated revenue per employee is $217,000
  • Xencor's total funding is $133.4M.

Employee Data

  • Xencor has 356 Employees.(i)
  • Xencor grew their employee count by 3% last year.

Xencor's People

NameTitleEmail/Phone
1
SVP, Chief Financial OfficerReveal Email/Phone
2
SVP, Clinical Development and Medical AffairsReveal Email/Phone
3
VP, BiometricsReveal Email/Phone
4
VP, CMC OperationsReveal Email/Phone
5
VP, FinanceReveal Email/Phone
6
Head Statistical ProgrammingReveal Email/Phone
7
VP, Nonclinical & Bioanalytical DevelopmentReveal Email/Phone
8
VP, Development Sciences, Head Protein Sciences & TechnologyReveal Email/Phone
9
Head, Corporate Communications and Investor RelationsReveal Email/Phone
10
VP Translational BiologyReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Xencor?

Antibodies by Design Antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. At Xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics antibodies that target new biological mechanisms and are more potent, safer and longer lasting to improve patient outcomes and quality of life. Our XmAb antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. This combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. The XmAb® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by Xencor and by pharmaceutical partners. Xencor is also discovering biologics products that improve the performance of old antibody drugs, known as biosuperiors, to benefit patients, ease compliance and help reduce costs.

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power

$133.4M

Total Funding

356

Number of Employees

$77.3M

Revenue (est)

3%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Xencor News

2022-04-20 - Xencor to Host First Quarter 2022 Financial Results Webcast ...

Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer...

2022-04-06 - Xencor, Inc. (NASDAQ:XNCR) Given Average Rating of “Buy ...

Several equities analysts recently issued reports on XNCR shares. BMO Capital Markets started coverage on Xencor in a research report on Friday,...

2022-03-30 - Xencor Presents Data from Multiple Preclinical XmAb ...

Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer...

2021-08-05 - Xencor : Reports Second Quarter 2021 Financial Results (Form 8-K)

Xencor Reports Second Quarter 2021 Financial Results -- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif.--August 4, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatm ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$138.7M41135%N/A
#2
N/A41842%N/A
#3
$98.3M4373%N/A
#4
N/A5861%N/A
#5
$153.1M6306%N/A

Xencor Funding

DateAmountRoundLead InvestorsReference
2005-10-19$20.0MDZen Investments LLCArticle
2006-07-12$6.0MUndisclosedNovo NordiskArticle
2006-10-20$45.0MUndisclosedMedImmune Ventures IncArticle
2007-10-26$15.0MERBC Capital MarketsArticle
2013-12-04$80.5MUndisclosedCredit Suisse Securities (USA) LLCArticle
2015-03-03$122.9MUndisclosedLeerink PartnersArticle
2016-12-02$126.5MUndisclosedLeerink PartnersArticle
2018-03-20$UndisclosedUndisclosedLeerink PartnersArticle